WO2025253179 - BRINCIDOFOVIR FOR REDUCING INFECTIOUS POLYOMAVIRUS PRODUCTION
National phase entry is expected:
Publication Number
WO/2025/253179
Publication Date
11.12.2025
International Application No.
PCT/IB2025/000294
International Filing Date
05.06.2025
Title **
[English]
BRINCIDOFOVIR FOR REDUCING INFECTIOUS POLYOMAVIRUS PRODUCTION
[French]
BRINCIDOFOVIR POUR RÉDUIRE LA PRODUCTION DE POLYOMAVIRUS INFECTIEUX
Applicants **
SYMBIO PHARMACEUTICALS LIMITED
Inventors
LUKACHER, Aron Eliot
LAUVER, Matthew David
HAZAMA, Masatoshi
FUKUSHIMA, Koji
Priority Data
63/656,676
06.06.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
JPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2643 | |
| EPO | Filing, Examination, Granting | 19225 | |
| Japan | Filing, Examination, Granting | 2307 | |
| South Korea | Filing, Examination, Granting | 2964 | |
| USA | Filing, Examination, Granting | 6340 |
Total:
33,479
Contact Us
Abstract[English]
A method of reducing infectious polyomavirus production in the brain or kidney of a human subject in need thereof, the method comprising administering a therapeutically effective amount of brincidofovir (BCV) or a pharmaceutically acceptable salt thereof to the human subject. A method of decreasing the risk of infectious polyomavirus production in the brain or kidney of a human subject in need thereof, the method comprising administering a therapeutically effective amount of brincidofovir (BCV) or a pharmaceutically acceptable salt thereof to the human subject.[French]
L'invention concerne un procédé de réduction de la production de polyomavirus infectieux dans le cerveau ou le rein d'un sujet humain en ayant besoin, le procédé comprenant l'administration d'une quantité thérapeutiquement efficace de brincidofovir (BCV) ou d'un sel pharmaceutiquement acceptable de celui-ci au sujet humain. L'invention concerne un procédé de diminution du risque de production de polyomavirus infectieux dans le cerveau ou le rein d'un sujet humain en ayant besoin, le procédé comprenant l'administration d'une quantité thérapeutiquement efficace de brincidofovir (BCV) ou d'un sel pharmaceutiquement acceptable de celui-ci au sujet humain.